Gilead reported 2025 revenue of $29.44 billion and Q1 2026 revenue of $6.96 billion. The thesis turns on whether HIV durability and cash generation can keep funding oncology, inflammation and pipeline expansion while patent, clinical and debt risks stay controlled.